Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | LATS1 | O95835 | 5/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | AOC1 | P19801 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25777526 | 0.84 | RPS6KA3 (0.45) | RPS6KA3LOXL2LATS1LATS2TGFBR1 | |
| SCHEMBL1858846 | 0.83 | RPS6KA3 (0.44) | RPS6KA3LOXL2LATS1LATS2TGFBR1 | |
| SCHEMBL14219235 | 0.83 | RPS6KA3 (0.44) | RPS6KA3LOXL2LATS1LATS2NUDT1 | |
| SCHEMBL25947271 | 0.83 | RPS6KA3 (0.44) | RPS6KA3LOXL2LATS1LATS2NUDT1 | |
| SCHEMBL30824555 | 0.83 | LOXL2 (0.44) | RPS6KA3LOXL2LATS1LATS2NUDT1 | |
| SCHEMBL1854863 | 0.83 | RPS6KA3 (0.47) | RPS6KA3LOXL2LATS1LATS2TGFBR1 | |
| SCHEMBL26916789 | 0.83 | LOXL2 (0.44) | RPS6KA3LOXL2LATS1LATS2NUDT1 | |
| SCHEMBL459016 | 0.83 | RPS6KA3 (0.47) | RPS6KA3LOXL2LATS1LATS2TGFBR1 | |
| SCHEMBL22304214 | 0.83 | RPS6KA3 (0.44) | RPS6KA3LOXL2LATS1LATS2NUDT1 | |
| SCHEMBL9004127 | 0.82 | RPS6KA3 (0.50) | RPS6KA3LOXL2LATS1LATS2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-7279493-B2 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | EURO-CELTIQUE S.A. | 2007-10-09 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070142360-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-08 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7157462-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | RPS6KA3 490/4885LOXL2 3088/4885LATS1 335/4885 |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | RPS6KA3 857/4885LOXL2 4524/4885LATS1 4468/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | RPS6KA3 3186/4885LOXL2 3968/4885LATS1 4199/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | RPS6KA3 3186/4885LOXL2 3968/4885LATS1 4199/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | RPS6KA3 129/4885LOXL2 3282/4885LATS1 209/4885 |
| US-20070142360-A1 | Therapeutic agents useful for treating pain | OPRL1, OPRK1, ARRB1 | RPS6KA3 314/4885LOXL2 3761/4885LATS1 4243/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | RPS6KA3 425/4885LOXL2 2918/4885LATS1 1165/4885 |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | ESR1, ECE1, ESYT1 | RPS6KA3 1954/4885LOXL2 1138/4885LATS1 441/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | RPS6KA3 2197/4885LOXL2 1513/4885LATS1 3205/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | RPS6KA3 2648/4885LOXL2 1735/4885LATS1 3870/4885 |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | TRPV1, OPRL1, CNR2 | RPS6KA3 853/4885LOXL2 1694/4885LATS1 3137/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | RPS6KA3 544/4885LOXL2 1714/4885LATS1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.